What is Rxsight?
Rxsight is at the forefront of ophthalmic technology, developing an office-based solution that enables doctors and patients to predictably optimize vision following cataract surgery. Founded in 1997 and headquartered in California, the company's proprietary technology aims to enhance the outcomes of intraocular lens (IOL) implantation, addressing a critical need in the post-surgical vision correction market. The company's focus on predictable outcomes positions it as a key player in the medtech sector.
How much funding has Rxsight raised?
Rxsight has raised a total of $317.8M across 7 funding rounds:
Private Equity
$8.5M
Private Equity
$12.7M
Debt
$17M
Private Equity
$52M
Private Equity
$50M
Debt
$60M
Share Placement
$117.6M
Private Equity (2009): $8.5M, investors not publicly disclosed
Private Equity (2011): $12.7M, investors not publicly disclosed
Debt (2015): $17M, investors not publicly disclosed
Private Equity (2015): $52M featuring Balance Point Capital Partners, H.I.G. BioVentures, Longitude Capital, and RA Capital Management
Private Equity (2017): $50M, investors not publicly disclosed
Debt (2020): $60M with participation from Oxford Finance
Share Placement (2021): $117.6M, investors not publicly disclosed
Key Investors in Rxsight
Oxford Finance
Oxford Finance, founded in 2002 and headquartered in Alexandria, Virginia, is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide. Their involvement indicates a strategic debt financing approach to support Rxsight's growth.
H.I.G. BioVentures
H.I.G. Capital is a leading global alternative investment firm with a focus on the mid-cap segment. H.I.G. BioVentures specifically targets healthcare and life sciences companies, suggesting a strategic investment in Rxsight's medical technology.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on healthcare and life science companies. Their investment in Rxsight highlights a commitment to innovative solutions that aim to improve patient lives through advancements in medical technology.
What's next for Rxsight?
With the recent influx of major strategic investment, Rxsight is poised for accelerated expansion and further technological advancement. The enterprise-level backing suggests a strategic focus on scaling operations, enhancing research and development efforts, and potentially broadening market penetration. This capital infusion will likely support the company's mission to refine its IOL enhancement technology and solidify its position as a leader in vision optimization solutions for cataract surgery patients.
See full Rxsight company page
